DIR Return Create A Forum - Home
       ---------------------------------------------------------
       luther pike seattle | Luther Pike Seattle Elastic Tuxedo Y Back
  HTML https://httpsxulnazcomproduc.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: General Discussion
       *****************************************************
       #Post#: 15--------------------------------------------------
        But actually provide
       By: Muslima Akter Date: August 29, 2023, 11:09 pm
       ---------------------------------------------------------
       The FDA's guidance lists considerations for data collection and
       safety--in one example, the FDA suggests that two different
       experts are available to monitor trial participants who receive
       psychedelic treatments. Ultimately, the guidance is geared
       toward pushing research forward to help bring new therapies into
       the market. "Forging this path forward shows access for other
       psychedelic drugs that are in various stages of clinical trials
       and shows that there is a commitment from the FDA to again, not
       only just approve them, a path for accessibility," says Payton
       Nyquvest, the CEO and co-founder of Numinus Health, a
       psychedelics-assisted therapy provider. Numinus offers ketamine,
       psilocybin, and MDMA therapy, and operates 13 wellness clinics
       in the U.S. and Canada (its two locations in the U.S. are in
       Utah and Arizona, and those only offer ketamine for now). In
       addition to the FDA, advocacy groups are also outlining
       protocols.
       In August, the American Psychedelic Practitioners Association,
       a nonprofit working to integrate psychedelic-assisted therapy
       into the U.S. health care system, released its own first-ever
       guidelines for therapists who will be administering psychedelics
       in clinical settings. More support may be on the way from
       Congress as lawmakers from both sides of the aisle work to
       include a provision in the annual defense spending package to
       funnel millions into research into these drugs. More states like
       USA Phone Number Data
  HTML https://dbtodata.com/usa-number-data/
       Massachusetts and
       California are also looking to legalize certain psychedelics,
       while Minnesota has assembled its own psychedelics task force.
       Estimates for the psychedelic market are in the billions for the
       U.S. market alone. Therapies like MDMA are being eyed, as it's
       murmured it could come to market in the U.S. as soon as next
       year, according to Nyquvest. The way Perry Salzhauer, an
       attorney at the New Orleans-based McGlinchey Stafford law firm,
       sees it, two verticals exist in the market: the pharmaceutical
       vertical, which is what the FDA guidance directly impacts, and
       the state-level psychedelic therapy treatment vertical. "The
       state vertical is probably a quicker path to generating
       revenue," Salzhauer, who co-chairs McGlinchey's cannabis
       industry group, says. But there's a catch, because, like
       cannabis, psychedelics are illegal at a federal level.
       [img]
  HTML https://github.com/mdsakib0012/image/blob/main/USA%20Phone%20Number%20Data.png?raw=true[/img]
  HTML https://dbtodata.com/usa-number-data/
       Going to be more of a challenge from a tax perspective," says
       Salzhauer, "because one of the advantages of going [with] the
       FDA pharmaceutical vertical is that you would not be subjected
       to Section 280E of the Internal Revenue Code, which is a
       punitive tax provision that applies to businesses that traffic
       in a controlled substance." For entrepreneurs working within the
       industry, Salzhauer advises that they figure out the vertical
       first. That also means that entrepreneurs should be thinking
       about their exit horizon, should they be interested in one,
       since investigatory drug processes take many years and are often
       significantly more expensive on the front end, he adds. While he
       admits it's probably too early to tell, Salzhauer hazards a
       guess that MDMA-based therapies are closer to receiving approval
       compared with other psychedelic therapies. As research continues
       and practitioners prepare for new treatments, there's clear
       interest from the public. A Harris Poll survey from January 2022
       showed that 65 percent of Americans with anxiety.
       *****************************************************